Comment
Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation
Affiliations
- PMID: 15989295
Item in Clipboard
Comment
Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation
ACP J Club.
2005 Jul-Aug.
No abstract available
Comment on
-
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.JAMA. 2005 Feb 9;293(6):690-8. doi: 10.1001/jama.293.6.690. JAMA. 2005. PMID: 15701910 Clinical Trial.
Similar articles
-
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Anadolu Kardiyol Derg. 2007. PMID: 17347079 Review. Turkish.
-
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.Am Heart J. 2006 Nov;152(5):967-73. doi: 10.1016/j.ahj.2006.06.024. Am Heart J. 2006. PMID: 17070169
-
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.Arch Intern Med. 2006 Apr 24;166(8):853-9. doi: 10.1001/archinte.166.8.853. Arch Intern Med. 2006. PMID: 16636210 Clinical Trial.
-
Trials and tribulations of non-inferiority: the ximelagatran experience.J Am Coll Cardiol. 2005 Dec 6;46(11):1986-95. doi: 10.1016/j.jacc.2005.07.062. Epub 2005 Nov 9. J Am Coll Cardiol. 2005. PMID: 16325029
-
Ximelagatran for stroke prevention in atrial fibrillation.Expert Rev Cardiovasc Ther. 2005 Jul;3(4):551-63. doi: 10.1586/14779072.3.4.551. Expert Rev Cardiovasc Ther. 2005. PMID: 16076267 Review.